Updates in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma from ASH 2021

Expert perspective on the management of multiple myeloma at first relapse in the context of recent clinical data from the ASH 2021 Annual Meeting.

Insight on results from the MonumenTAL-1 and MajesTEC-1 studies, which evaluated bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Amrita Y. Krishnan, MD, considers where bispecific antibodies will fit into the multiple myeloma treatment paradigms as single-agent or combination therapy.

Closing out her discussion on the management of newly diagnosed and relapsed/refractory multiple myeloma, Amrita Y. Krishnan, MD, shares key takeaways from the ASH 2021 Annual Meeting.

Updated results from the GRIFFIN study, which combined daratumumab with RVd in patients with transplant-eligible newly diagnosed multiple myeloma.

Expert perspective on results from the MASTER study analyzing daratumumab in combination with KRd in transplant-eligible newly diagnosed multiple myeloma.

In the context of transplant-ineligible newly diagnosed multiple myeloma, Saad Usmani, MD, considers the role of triplet versus quadruplet therapy.

Closing out his discussion on newly diagnosed multiple myeloma, Saad Usmani, MD, considers the approval and use of subcutaneous daratumumab.

Insight on the BELLINI study, which added venetoclax to bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma.

In relapsed/refractory multiple myeloma, a recent study tested the addition of venetoclax to daratumumab and dexamethasone.

Saad Usmani, MD, shares his excitement for additional clinical trial data in multiple myeloma presented at the ASH 2021 annual meeting.

Closing out his discussion on the ASH 2021 meeting, Saad Usmani, MD, shares key takeaways for clinical practice in multiple myeloma.